Wrapmanager Inc. Sells 16,043 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Wrapmanager Inc. reduced its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 41.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,356 shares of the medical technology company’s stock after selling 16,043 shares during the quarter. Wrapmanager Inc.’s holdings in Alphatec were worth $205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Atria Investments Inc grew its holdings in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after buying an additional 1,460 shares during the last quarter. Rhumbline Advisers raised its holdings in Alphatec by 1.3% in the 4th quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company’s stock worth $1,277,000 after acquiring an additional 1,746 shares during the last quarter. Entropy Technologies LP boosted its stake in Alphatec by 14.9% during the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock valued at $120,000 after purchasing an additional 2,800 shares during the last quarter. R Squared Ltd purchased a new stake in Alphatec during the 4th quarter valued at $29,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Insider Activity at Alphatec

In other news, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the completion of the transaction, the chief executive officer now directly owns 5,501,715 shares in the company, valued at approximately $66,020,580. This represents a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 222,376 shares of company stock worth $2,557,148. 22.80% of the stock is owned by company insiders.

Alphatec Trading Down 1.9 %

Alphatec stock opened at $10.56 on Wednesday. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $15.41. The company has a market cap of $1.50 billion, a P/E ratio of -8.25 and a beta of 1.43. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business has a 50-day simple moving average of $10.52 and a two-hundred day simple moving average of $8.33.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ATEC shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Barclays upped their target price on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC raised their price target on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.